Skip to main content

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

Publication ,  Conference
Secord, AA; Tritchler, D; Liu, Y; Starr, MD; Brady, JC; Lankes, HA; Hurwitz, H; Mannel, RS; Tewari, KS; O'Malley, DM; Gray, HJ; Fujiwara, K ...
Published in: Journal of Clinical Oncology
May 20, 2016

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

5521 / 5521

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Tritchler, D., Liu, Y., Starr, M. D., Brady, J. C., Lankes, H. A., … Nixon, A. B. (2016). Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218. In Journal of Clinical Oncology (Vol. 34, pp. 5521–5521). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.5521
Secord, Angeles Alvarez, David Tritchler, Yingmiao Liu, Mark D. Starr, John C. Brady, Heather A. Lankes, Herbert Hurwitz, et al. “Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.” In Journal of Clinical Oncology, 34:5521–5521. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5521.
Secord AA, Tritchler D, Liu Y, Starr MD, Brady JC, Lankes HA, et al. Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5521–5521.
Secord, Angeles Alvarez, et al. “Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 5521–5521. Crossref, doi:10.1200/jco.2016.34.15_suppl.5521.
Secord AA, Tritchler D, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz H, Mannel RS, Tewari KS, O’Malley DM, Gray HJ, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB. Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5521–5521.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

5521 / 5521

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences